City of Hope (T Cell Manufacturing) vs Novartis: CDMO Comparison
How does City of Hope (T Cell Manufacturing) compare to Novartis for CAR-T manufacturing?
Side-by-side comparison of City of Hope (T Cell Manufacturing) and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (15 vs 3) — a deeper regulatory paper trail.
- City of Hope (T Cell Manufacturing) carries a cleaner inspection mix — no OAI classifications versus 2 for Novartis.
- Novartis holds 59 active EMA GMP certificates; City of Hope (T Cell Manufacturing) does not appear in EudraGMDP.
- Novartis maintains 3 MHRA / UK GMP certificates; City of Hope (T Cell Manufacturing) does not.
On a 13-modality CDMO landscape, both City of Hope (T Cell Manufacturing) and Novartis qualify as CAR-T manufacturers; Novartis carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both City of Hope (T Cell Manufacturing) and Novartis qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: City of Hope (T Cell Manufacturing) vs Novartis
How does City of Hope (T Cell Manufacturing) compare to Novartis for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, City of Hope (T Cell Manufacturing) is 84/100 and Novartis is 88/100; City of Hope (T Cell Manufacturing) has 3 FDA inspections on record vs 15 for Novartis; European coverage is 0 active EMA+MHRA certificates for City of Hope (T Cell Manufacturing) vs 62 for Novartis. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, City of Hope (T Cell Manufacturing) or Novartis?
City of Hope (T Cell Manufacturing) has 3 FDA inspections on record (NAI 2 / VAI 1 / OAI 0) and 0 warning letters. Novartis has 15 FDA inspections on record (NAI 6 / VAI 7 / OAI 2) and 0 warning letters.
How do City of Hope (T Cell Manufacturing) and Novartis compare on European GMP coverage?
City of Hope (T Cell Manufacturing) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Novartis holds 59 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — City of Hope (T Cell Manufacturing) or Novartis?
City of Hope (T Cell Manufacturing) is matched to 213 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 137. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — City of Hope (T Cell Manufacturing) or Novartis?
Both City of Hope (T Cell Manufacturing) and Novartis are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →